Christopher Rovaldi Sells 2,266 Shares of Acceleron Pharma Inc (XLRN) Stock

Acceleron Pharma Inc (NASDAQ:XLRN) SVP Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $42.42, for a total value of $96,123.72. Following the completion of the sale, the senior vice president now owns 52,977 shares in the company, valued at $2,247,284.34. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of Acceleron Pharma Inc (NASDAQ XLRN) opened at $42.11 on Friday. Acceleron Pharma Inc has a 1 year low of $23.07 and a 1 year high of $44.80. The firm has a market capitalization of $1,850.00, a P/E ratio of -16.32 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. During the same period in the previous year, the company posted ($0.55) earnings per share. The firm’s revenue was up .0% on a year-over-year basis. equities analysts forecast that Acceleron Pharma Inc will post -2.65 EPS for the current fiscal year.

XLRN has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a research report on Monday, December 11th. Barclays lifted their price objective on Acceleron Pharma from $42.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 20th. UBS Group reiterated a “buy” rating and issued a $50.00 price objective (up from $36.00) on shares of Acceleron Pharma in a research report on Tuesday, September 12th. Finally, ValuEngine lowered Acceleron Pharma from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $44.56.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP purchased a new position in Acceleron Pharma during the third quarter valued at $1,496,000. Iguana Healthcare Management LLC purchased a new position in Acceleron Pharma during the third quarter valued at $2,612,000. Point72 Asset Management L.P. purchased a new position in Acceleron Pharma during the third quarter valued at $2,721,000. Granahan Investment Management Inc. MA raised its stake in Acceleron Pharma by 15.2% during the third quarter. Granahan Investment Management Inc. MA now owns 217,091 shares of the biopharmaceutical company’s stock valued at $8,102,000 after buying an additional 28,694 shares during the last quarter. Finally, Perceptive Advisors LLC raised its stake in Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after buying an additional 905,000 shares during the last quarter. Institutional investors own 85.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2018/01/06/christopher-rovaldi-sells-2266-shares-of-acceleron-pharma-inc-xlrn-stock.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

What are top analysts saying about Acceleron Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit